Recent Clinical Successes in Liposomal Nanomedicines

International journal of drug discovery and pharmacology Pub Date : 2023-02-03 DOI:10.53941/ijddp.0201009

Wenjie Gu, G. Andrews, Yiwei Tian

{"title":"Recent Clinical Successes in Liposomal Nanomedicines","authors":"Wenjie Gu, G. Andrews, Yiwei Tian","doi":"10.53941/ijddp.0201009","DOIUrl":null,"url":null,"abstract":"Review\nRecent Clinical Successes in Liposomal Nanomedicines\n\nWenjie Gu , Gavin P. Andrews , and Yiwei Tian , *\n\n\nSchool of Pharmacy, Queen’s University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, UK.\n* Correspondence: y.tian@qub.ac.uk\n \n \nReceived: 19 December 2022\nAccepted: 26 January 2023\nPublished: 3 February 2023\n \n\nAbstract: The intrinsic limitations of cancer therapies promoted the development of safer liposomal nanocarriers capable of better distributing the payload away from normal tissues. Since then, liposomal nanocarriers have been considered the primary drug delivery system for many active pharmaceutical ingredients. These systems are now frequently investigated for the treatment of many infectious diseases. Along with the tremendous progress in the anticancer and antifungal liposomal nanomedicines, we have also gradually realised the difficulties associated with the existing liposomal nanocarrier designs. A better understanding of the nanocarrier-bio interactions may provide a new paradigm in liposomal nanocarrier design and better clinical endpoint efficacy. This short review focuses on the progress and benefits of two market-approved liposomal nanomedicines for cancer and fungal treatments.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of drug discovery and pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53941/ijddp.0201009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Review Recent Clinical Successes in Liposomal Nanomedicines Wenjie Gu , Gavin P. Andrews , and Yiwei Tian , * School of Pharmacy, Queen’s University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, UK. * Correspondence: y.tian@qub.ac.uk Received: 19 December 2022 Accepted: 26 January 2023 Published: 3 February 2023 Abstract: The intrinsic limitations of cancer therapies promoted the development of safer liposomal nanocarriers capable of better distributing the payload away from normal tissues. Since then, liposomal nanocarriers have been considered the primary drug delivery system for many active pharmaceutical ingredients. These systems are now frequently investigated for the treatment of many infectious diseases. Along with the tremendous progress in the anticancer and antifungal liposomal nanomedicines, we have also gradually realised the difficulties associated with the existing liposomal nanocarrier designs. A better understanding of the nanocarrier-bio interactions may provide a new paradigm in liposomal nanocarrier design and better clinical endpoint efficacy. This short review focuses on the progress and benefits of two market-approved liposomal nanomedicines for cancer and fungal treatments.

查看原文本刊更多论文

脂质体纳米药物的最新临床成功

纳米脂质体药物的临床研究进展[j]顾文杰，Gavin P. Andrews，田一伟，*贝尔法斯特女王大学药学院，英国贝尔法斯特里斯本路97号，bt7bl。摘要:癌症治疗的内在局限性促进了更安全的脂质体纳米载体的发展，这些脂质体纳米载体能够更好地将有效载荷分布在正常组织之外。从那时起，脂质体纳米载体被认为是许多活性药物成分的主要药物传递系统。这些系统现在经常被研究用于治疗许多传染病。随着抗癌和抗真菌纳米脂质体药物的巨大进展，我们也逐渐认识到现有脂质体纳米载体设计的困难。更好地了解纳米载体与生物的相互作用可能为脂质体纳米载体的设计和更好的临床终点疗效提供新的范例。这篇简短的综述着重于两种市场批准的用于癌症和真菌治疗的脂质体纳米药物的进展和益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of drug discovery and pharmacology

自引率

0.00%

发文量